Spectrum Pharmaceuticals Announces Appointment of Luigi Lenaz, M.D., as Lead Director
October 18 2016 - 7:00AM
Business Wire
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology
company with fully integrated commercial and drug development
operations with a primary focus in Hematology and Oncology, today
announced that independent director Luigi Lenaz, M.D., has been
appointed to the newly created position of Lead Director.
“Dr. Lenaz’s unique scientific background and deep business
expertise make him ideally suited for the newly created Lead
Director position,” said Rajesh C. Shrotriya, M.D., Chairman and
Chief Executive Officer of Spectrum Pharmaceuticals. “Dr. Lenaz has
provided invaluable advice historically, and I look forward to
working closely with him in his new role.”
Luigi Lenaz, M.D., is a world-renowned oncologist and a leading
scientist authority in developing cancer drugs. An accomplished
oncologist before joining the industry, he has conducted research
at prominent institutions including Roswell Park Memorial
Institute, Memorial Sloan-Kettering Cancer Center, and the National
Cancer Institute in Milan. He is an experienced anti-cancer drug
developer, with over 40 years of experience in the pharmaceutical
industry and has played key roles in developing numerous major
cancer drugs including Taxol®, Adriamycin®, etoposide, amascrine,
cisplatin, and carboplatin. Dr. Lenaz served as a Post Doctoral
Fellow at both the Memorial Sloan-Kettering Cancer Center in New
York and the National Cancer Institute in Milan, Italy. He received
his medical degree at the University of Bologna Medical School in
Bologna, Italy in 1966.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company
focused on acquiring, developing, and commercializing drug
products, with a primary focus in Hematology and Oncology. Spectrum
currently markets six hematology/oncology drugs, and has an
advanced stage pipeline that has the potential to transform
the Company. Spectrum's strong track record for in-licensing and
acquiring differentiated drugs, and expertise in clinical
development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase
3 studies. More information on Spectrum is available
at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future,
including certain company milestones, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse
pipeline of late-stage clinical and commercial products, the timing
and results of FDA decisions, and any statements that relate to the
intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that Spectrum’s existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that
our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and
quality control and other risks that are described in further
detail in the Company's reports filed with the Securities and
Exchange Commission. The Company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of
Spectrum Pharmaceuticals, Inc. and its affiliate. REDEFINING CANCER
CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned
by Spectrum Pharmaceuticals, Inc. Any other trademarks are the
property of their respective owners.
© 2016 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161018005275/en/
Spectrum Pharmaceuticals, Inc.Shiv KapoorVice President,
Strategic Planning & Investor
Relations702-835-6300InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024